NCT02054481 - BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab | Biotech Hunter

Enrollment

166

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

July 31, 2015

Conditions

Psoriasis

Interventions

DRUG

BI 655066

Medium dose

DRUG

BI 655066

High dose

DRUG

Ustekinumab

DRUG

BI 655066

Low dose

Trial Locations (32)

Unknown

1311.2.10010 Boehringer Ingelheim Investigational Site, Los Angeles

1311.2.10013 Boehringer Ingelheim Investigational Site, Port Orange

1311.2.10003 Boehringer Ingelheim Investigational Site, Arlington Hts

1311.2.10002 Boehringer Ingelheim Investigational Site, Bay City

1311.2.10004 Boehringer Ingelheim Investigational Site, Fridley

1311.2.10001 Boehringer Ingelheim Investigational Site, East Windsor

1311.2.10009 Boehringer Ingelheim Investigational Site, Verona

1311.2.10007 Boehringer Ingelheim Investigational Site, Raleigh

1311.2.10005 Boehringer Ingelheim Investigational Site, Portland

1311.2.10006 Boehringer Ingelheim Investigational Site, Dallas

1311.2.10011 Boehringer Ingelheim Investigational Site, Houston

1311.2.10012 Boehringer Ingelheim Investigational Site, Spokane

1311.2.20002 Boehringer Ingelheim Investigational Site, Markham

1311.2.20005 Boehringer Ingelheim Investigational Site, Peterborough

1311.2.20003 Boehringer Ingelheim Investigational Site, Waterloo

1311.2.20004 Boehringer Ingelheim Investigational Site, Sainte-Foy

1311.2.35802 Boehringer Ingelheim Investigational Site, Helsinki

1311.2.35801 Boehringer Ingelheim Investigational Site, Turku

1311.2.33005 Boehringer Ingelheim Investigational Site, Marseille

1311.2.33002 Boehringer Ingelheim Investigational Site, Nice

1311.2.33001 Boehringer Ingelheim Investigational Site, Paris

1311.2.33004 Boehringer Ingelheim Investigational Site, Pessac

1311.2.33003 Boehringer Ingelheim Investigational Site, Rouen

1311.2.33006 Boehringer Ingelheim Investigational Site, Toulouse

1311.2.49001 Boehringer Ingelheim Investigational Site, Berlin

1311.2.49003 Boehringer Ingelheim Investigational Site, Dresden

1311.2.49005 Boehringer Ingelheim Investigational Site, Lübeck

1311.2.49002 Boehringer Ingelheim Investigational Site, Mainz

1311.2.49004 Boehringer Ingelheim Investigational Site, Münster

1311.2.47002 Boehringer Ingelheim Investigational Site, Ålesund

1311.2.47001 Boehringer Ingelheim Investigational Site, Oslo

1311.2.46001 Boehringer Ingelheim Investigational Site, Stockholm